Merkel Cell Carcinoma: Chemotherapy and Emerging New Therapeutic Options
Open Access
- 10 February 2013
- journal article
- review article
- Published by Hindawi Limited in Journal of Skin Cancer
- Vol. 2013, 1-9
- https://doi.org/10.1155/2013/327150
Abstract
Merkel cell carcinoma (MCC) is a rare neuroendocrine skin tumor that typically occurs in elderly, immunosuppressed patients. Infection with Merkel cell virus (MCV) and immunosuppression play an important role in the development of MCC. Different staging systems make it difficult to compare the existing clinical data. Furthermore, there predominantly exist single case reports and case series, but no randomized controlled trials. However, it is necessary to develop further therapy options because MCC tends to grow rapidly and metastasizes early. In the metastatic disease, therapeutic attempts were made with various chemotherapeutic combination regimens. Because of the high toxicity of these combinations, especially those established in SCLC, and regarding the unsatisfying results, the challenge is to balance the pros and cons of chemotherapy individually and carefully. Up to now, emerging new therapy options as molecular-targeted agents, for example, pazopanib, imatinib, or somatostatin analogues as well as immunologicals, for example, imiquimod and interferons, also showed less success concerning the disease-free response rates. According to the literature, neither chemotherapy nor molecular-targeted agents or immunotherapeutic strategies have shown promising effects in the therapy of the metastatic disease of MCC so far. There is a great demand for randomized controlled studies and a need for an MCC registry and multicenter clinical trials due to the tumors curiosity.Keywords
This publication has 66 references indexed in Scilit:
- Merkel cell carcinomaCurrent Opinion in Oncology, 2012
- Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of SurvivalJournal of Clinical Oncology, 2011
- Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging systemJournal of the American Academy of Dermatology, 2010
- A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin)American Journal of Clinical Oncology, 2010
- Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T AntigensJournal of Virology, 2010
- Skin cancers associated with HIV infection and solid‐organ transplantation among elderly adultsInternational Journal of Cancer, 2010
- Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU featuresJournal of the American Academy of Dermatology, 2008
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07Journal of Clinical Oncology, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002